For adult periodontitis. ANDA 65287, held by Pharmobedient. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 65287 (Doxycycline Hyclate), held by Pharmobedient, was first approved by FDA on Feb 28, 2006, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Doxycycline Hyclate is indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 28, 2006 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 20MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Apr 4, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Feb 28, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters